Table 1 Characteristics of the included studies evaluating the relationship between circulating chemerin levels and preeclampsia
From: Circulating chemerin levels in preeclampsia: a systematic review and meta-analysis
No | First author | Year | Country | Study design | Specimen type | Detection method | Before/after PE diagnosis | Classification of PE | GA at sampling (weeks) | Sample size | Chemerin (ng/ml) | Age (years) | BMI (kg/m2) | Sen (%) | Spe (%) | Cut-off (ng/mL) | AUC | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
control | PE | control | PE | control | PE | control | PE | control | PE | |||||||||||||
1 | Stepan | 2011 | Germany | Cross-sectional | Serum | ELISA | After | Total | 28.86 (25.57–37) a | 29.57 (23.86–39.86) a | 37 | 37 | 205.82 ± 33.48 | 248.55 ± 57.36 | 30 (18–40) a | 31 (19–39) a | 22.0 (18.4–43.0) a | 22.4 (16.9–31.2) a | NA | NA | NA | NA |
2 | Al-Refai | 2012 | Saudi Arabia | Cross-sectional | Serum | ELISA | After | Total | 33.76 ± 3.29 | 32.68 ± 4.88 | 30 | 29 | 174.40 ± 29.17 | 349.90 ± 147.92 | 31.96 ± 5.27 | 34.37 ± 5.79 | 29.36 ± 2.69 | 30.46 ± 1.3 | NA | NA | NA | NA |
|  |  |  |  |  |  |  |  | Mild |  |  |  | 19 |  | 281.95 ± 144.54 |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  | Severe |  |  |  | 10 |  | 479 ± 158.56 |  |  |  |  |  |  |  |  |
3 | Duan | 2012 | China | Cross-sectional | Serum | ELISA | After | Total | 36.38 ± 3.59 | 35.83 ± 3.42 | 72 | 72 | 210.80 ± 47.34 | 258.85 ± 86.64 | 28.83 ± 4.32 | 29.19 ± 5.06 | 20.83 ± 2.75 ▲ | 23.24 ± 3.31 ▲ | NA | NA | NA | NA |
|  |  |  |  |  |  |  |  | Mild |  |  |  | 49 |  | 228.1 ± 87.99 |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  | Severe |  |  |  | 23 |  | 289.6 ± 74.43 |  |  |  |  |  |  |  |  |
4 | Xu | 2014 | China | Prospective cohort | Serum | ELISA | Before | Total | 10.64 ± 0.61 | 10.67 ± 0.49 | 477 | 41 | 181.4 ± 78.6 | 312.1 ± 112.7 | 25.0 ± 4.7 | 27.2 ± 4.4 | 22.6 ± 2.5 ▲ | 25.4 ± 2.6 ▲ | 87.8 | 75.7 | 183.5 | 0.766 |
|  |  |  |  |  |  |  |  | Mild |  |  |  | 23 |  | 270.3 ± 91.8 |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  | Severe |  |  |  | 18 |  | 365.5 ± 116.5 |  |  |  |  |  |  |  |  |
5 | Turgut | 2015 | Turkey | Cross-sectional | Serum | ELISA | After | Total | 35.5 (26–38) b | 34.5 (25–40) b | 32 | 32 | 163.39 ± 13.77 | 218.84 ± 17.40 | 31.03 ± 7.12 | 31.28 ± 8.05 | 24.5 (21.2–24.9) b▲ | 24.6 (20.8–24.9) b ▲ | NA | NA | NA | NA |
6 | Wang | 2015 | China | Cross-sectional | Serum | ELISA | After | Total | 39.3 ± 0.9 |  | 28 | 60 | 220.00 ± 50.78 |  | 28.2 ± 4.8 |  | 26.28 ± 3.16 |  | NA | NA | NA | NA |
|  |  |  |  |  |  |  |  | Mild |  | 38.5 ± 1.6 |  | 30 |  | 330.23 ± 56.22 |  | 27.9 ± 6.5 |  | 27.49 ± 2.68 |  |  |  |  |
|  |  |  |  |  |  |  |  | Severe |  | 37.4 ± 2.9 |  | 30 |  | 493.83 ± 105.23 |  | 28.5 ± 5.5 |  | 28.65 ± 3.98 |  |  |  |  |
7 | Cetin | 2017 | Turkey | Cross-sectional | Serum | ELISA | After | Total | NA |  | 46 | 88 | 199.96 ± 28.05 |  | 26.59 ± 3.68 |  | 25.62 ± 2.24 |  | 95.5 | 95.7 | 252 | NA |
|  |  |  |  |  |  |  |  | Mild |  | NA |  | 45 |  | 322.11 ± 37.60 |  | 28.11 ± 5.02 |  | 26.86 ± 1.93 |  |  |  |  |
|  |  |  |  |  |  |  |  | Severe |  | NA |  | 43 |  | 394.72 ± 100.01 |  | 27.65 ± 6.64 |  | 26.10 ± 2.35 |  |  |  |  |
8 | Murad | 2020 | Iraq | Cross-sectional | Serum | ELISA | After | Total | NA |  | 34 | 66 | 202.6 ± 21.1 |  | 26.23 ± 6.5 |  | 29.35 ± 4.1 |  | 89.3 | 94.1 | 228.5 | NA |
|  |  |  |  |  |  |  |  | Mild |  | NA |  | 33 |  | 227.49 ± 57.4 |  | 25.0 ± 5.0 |  | 26.61 ± 3.8 | NA | NA | NA | NA |
|  |  |  |  |  |  |  |  | Severe |  | NA |  | 33 |  | 435.06 ± 55.4 |  | 24.45 ± 6.3 |  | 28.43 ± 3.8 | 93.9 | 100 | 380.9 | NA |
9 | Tan | 2022 | China | Cross-sectional | Serum | ELISA | After | Total | 34 (28.86–36.29) b | 32.29 (27–36.14) b | 29 | 30 | 156.85 ± 87.33 | 285.93 ± 130 | 33 (28–37) b | 32 (30–36) b | 25 (23–31) b ▲ | 25 (22–28) b▲ | NA | NA | NA | NA |
10 | Bartho (1) | 2023 | Australia | Cross-sectional | Plasma | ELISA | After | Early-onset | 26.38 ± 0.98 | 29.65 ± 0.39 | 17 | 46 | 346.39 ± 137.42 | 487.71 ± 176.01 | 32.63 ± 0.95 | 30.83 ± 0.84 | 24.25 (28.93–20.55) b | 28.50 (35.20–26.00) b | NA | NA | NA | 0.75 |
11 | Bartho (2) | 2023 | South Africa | Cross-sectional | Plasma | ELISA | After | Severe | NA | NA | 15 | 26 | 111.82 ± 44.98 | 183.71 ± 94.12 | NA | NA | NA | NA | NA | NA | NA | NA |
12 | Bartho (3) | 2023 | Australia | Prospective cohort | Plasma | ELISA | Before | Total | 36.14 (35.71–36.57) b | 36.28 (35.57–36.57) b | 182 | 23 | 86.05 ± 20.18 | 111.08 ± 29.24 | 32 (29.75–35) b | 34 (32–37) b | 24.55 (22.29–28.12) b | 27.88 (24.14–30.66) b | NA | NA | NA | 0.8 |
13 | Chen | 2023 | China | Cross-sectional | Serum | ELISA | After | Total | 35.0 (34.0–36.0) b | 35.0 (34.0–36.0) b | 310 | 310 | 140.2 ± 53.5 | 171.80 ± 49.20 | 33.5 (31.0–36.0) b | 33.0 (30.0–36.0) b | 23.0 ± 3.3 ▲ | 22.5 ± 3.4 ▲ | NA | NA | NA | NA |